Low risk disease* |
Four cycles of VAMP (vinblastine, doxorubicin, methotrexate, prednisone) plus LD-IFRT administered after the second cycle of chemotherapy[1] |
Four cycles of COPP (cyclophosphamide, vincristine, procarbazine, prednisone)/ABV (doxorubicin, bleomycin, vinblastine) plus LD-IFRT[2] |
ABVE (doxorubicin, bleomycin, vincristine, etoposide), administered for two to four courses depending on response, followed by LD-IFRT[3] |
OEPA (vincristine, etoposide, prednisone, doxorubicin; for males) or OPPA (vincristine, procarbazine, prednisone, doxorubicin; for females) followed by LD-IFRT, depending upon the initial response to chemotherapy[4,5] |
Intermediate risk disease* |
Six cycles of COPP/ABV plus LD-IFRT[2] |
ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide), administered for three to five courses depending upon response, followed by LD-IFRT[4] |
Two cycles of OPPA (for males) or OEPA (for females), followed by two cycles of COPP (for females) or COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine, for males) plus LD-IFRT[4-6] |
High risk disease* |
ABVE-PC, administered for three to five courses depending upon response, followed by LD-IFRT[4] |
Two cycles of OPPA (for males) or OEPA (for females), followed by two cycles of COPP (for females) or COPDAC (for males) plus LD-IFRT[4-6] |
Two cycles of cytarabine/etoposide, COPP/ABV, and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus LD-IFRT[1] |
Four cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) with subsequent therapy dependent upon response; rapid responders: four cycles of COPP/ABV without IFRT (for females) or two cycles ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) with IFRT (for males); slow responders: four additional cycles of BEACOPP plus IFRT[7] |
Do you want to add Medilib to your home screen?